Litcius/Paper detail

Sulfonimide and Amide Derivatives as Novel PPARα Antagonists: Synthesis, Antiproliferative Activity, and Docking Studies

Alessandra Ammazzalorso, Isabella Bruno, Rosalba Florio, Laura De Lellis, Antonio Laghezza, Carmen Cerchia, Barbara De Filippis, Marialuigia Fantacuzzi, Letizia Giampietro, Cristina Maccallini, Paolo Tortorella, Serena Veschi, Fulvio Loiodice, Antonio Lavecchia, Alessandro Cama, Rosa Amoroso

2020ACS Medicinal Chemistry Letters21 citationsDOIOpen Access PDF

Abstract

lower than commercial PPARα antagonist GW6471 and a negligible toxicity on normal fibroblast cells. Docking studies were also performed to elucidate the binding mode of these compounds and to help interpretation of SAR data.

Topics & Concepts

Docking (animal)AntagonistAmideChemistryAgonistAntagonismMoietyStereochemistryTransactivationViability assayDU145Peroxisome proliferator-activated receptorReceptorPharmacologyBiochemistryCellCancer cellBiologyTranscription factorInternal medicineMedicineCancerNursingGeneLNCaPPeroxisome Proliferator-Activated ReceptorsPeptidase Inhibition and AnalysisProtein Degradation and Inhibitors
Sulfonimide and Amide Derivatives as Novel PPARα Antagonists: Synthesis, Antiproliferative Activity, and Docking Studies | Litcius